Journal de mycologie medicale最新文献

{"title":"Acquired resistance or tolerance? – in search of mechanisms underlying changes in the resistance profile of Candida albicans and Candida parapsilosis as a result of exposure to methotrexate","authors":"Katarzyna Góralska ,&nbsp;Małgorzata Szybka ,&nbsp;Filip Franciszek Karuga ,&nbsp;Dorota Pastuszak-Lewandoska ,&nbsp;Ewa Brzeziańska-Lasota","doi":"10.1016/j.mycmed.2024.101476","DOIUrl":"https://doi.org/10.1016/j.mycmed.2024.101476","url":null,"abstract":"<div><p>The increasing prevalence of fungal strains showing acquired resistance and multidrug resistance is an increasing therapeutic problem, especially in patients with a severely weakened immune system and undergoing chemotherapy. What is also extremely disturbing is the similarity of the resistance mechanisms of fungal cells and other eukaryotic cells, including human cells, which may contribute to the development of cross-resistance in fungi in response to substances used in e.g. anticancer treatment. An example of such a drug is methotrexate, which is pumped out of eukaryotic cells by ABC transmembrane transporters - in fungi, used to remove azoles from fungal cells.</p><p>For this reason, the aim of the study was to analyze the expression levels of genes: <em>ERG11, MDR1</em> and <em>CDR1</em>, potentially responsible for the occurrence of cross-resistance in <em>Candida albicans</em> and <em>Candida parapsilosis</em> as a result of fungal exposure to methotrexate (MTX).</p><p>In vitro exposure of <em>C. albicans</em> and <em>C. parapsilosis</em> strains to methotrexate showed a high increase in resistance to fluconazole and a partial increase in resistance to voriconazole. Analysis of the expression of resistance genes showed varied responses of the tested strains depending on the species. In the case of <em>C. albicans</em>, an increase in the expression of the <em>MDR1</em> gene was observed, and a decrease in <em>ERG11</em> and <em>CDR1</em>. However, for <em>C. parapsilosis</em> there was an increase in the expression of the <em>CDR1</em> gene and a decrease in <em>ERG11</em> and <em>MDR1</em>.</p><p>We noted the relationship between the level of resistance to voriconazole and the level of <em>ERG11</em> gene expression in <em>C. albicans</em>. This indicates that this type of relationship is different for each species. Our research confirms that the mechanisms by which fungi acquire resistance and develop cross-resistance are highly complex and most likely involve several pathways simultaneously. The emergence of multidrug resistance may be related to the possibility of developing tolerance to antimycotics by fungi.</p></div>","PeriodicalId":14824,"journal":{"name":"Journal de mycologie medicale","volume":"34 2","pages":"Article 101476"},"PeriodicalIF":3.6,"publicationDate":"2024-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1156523324000179/pdfft?md5=e3dd2110c7515973b5501e7989a8366b&pid=1-s2.0-S1156523324000179-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140163917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Itraconazole in human medicine and veterinary practice","authors":"Yamara V Sousa ,&nbsp;Marie G Santiago ,&nbsp;Bianca M de Souza ,&nbsp;Kelly M Keller ,&nbsp;Camila S F Oliveira ,&nbsp;Leonel Mendoza ,&nbsp;Raquel V R Vilela ,&nbsp;Gisele A C Goulart","doi":"10.1016/j.mycmed.2024.101473","DOIUrl":"10.1016/j.mycmed.2024.101473","url":null,"abstract":"<div><p>Diagnosis and management of fungal infections are challenging in both animals and humans, especially in immunologically weakened hosts. Due to its broad spectrum and safety profile when compared to other antifungals, itraconazole (ITZ) has been widely used in the treatment and prophylaxis of fungal infections, both in human and veterinary medicine. The dose and duration of management depend on factors such as the type of fungal pathogen, the site of infection, sensitivity to ITZ, chronic stages of the disease, the health status of the hosts, pharmacological interactions with other medications and the therapeutic protocol used. In veterinary practice, ITZ doses generally vary between 3 mg/kg and 50 mg/kg, once or twice a day. In humans, doses usually vary between 100 and 400 mg/day. As human and veterinary fungal infections are increasingly associated, and ITZ is one of the main medications used, this review addresses relevant aspects related to the use of this drug in both clinics, including case reports and different clinical aspects available in the literature.</p></div>","PeriodicalId":14824,"journal":{"name":"Journal de mycologie medicale","volume":"34 2","pages":"Article 101473"},"PeriodicalIF":3.6,"publicationDate":"2024-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140124978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antifungal activity of azoles, allylamines, and 8-hidroxiquinolines, alone and in combination, against Malassezia pachydermatis in vitro and in vivo","authors":"Simone Merkel ,&nbsp;Bruna Pippi ,&nbsp;Paula Reginatto ,&nbsp;Angélica R. Joaquim ,&nbsp;Gabriella R.M. Machado ,&nbsp;Daiane Heidrich ,&nbsp;Marina E. Furasté ,&nbsp;Jonnathan A. Silva ,&nbsp;Estela J.S. Konzen ,&nbsp;Maria Lúcia Scroferneker ,&nbsp;Saulo F. Andrade ,&nbsp;Alexandre M. Fuentefria ,&nbsp;Régis A. Zanette","doi":"10.1016/j.mycmed.2024.101475","DOIUrl":"https://doi.org/10.1016/j.mycmed.2024.101475","url":null,"abstract":"<div><p><em>Malassezia pachydermatis</em> is often reported as the causative agent of dermatitis in dogs. This study aims to evaluate the <em>in vitro</em> and <em>in vivo</em> antifungal activity of azoles and terbinafine (TRB), alone and in combination with the 8-hydroxyquinoline derivatives (8-HQs) clioquinol (CQL), 8-hydroxyquinoline-5-(n-4-chlorophenyl)sulfonamide (PH151), and 8-hydroxyquinoline-5-(n-4-methoxyphenyl)sulfonamide (PH153), against 16 <em>M. pachydermatis</em> isolates. Susceptibility to the drugs was evaluated by <em>in vitro</em> broth microdilution and time-kill assays. The <em>Toll</em>-deficient <em>Drosophila melanogaster</em> fly model was used to assess the efficacy of drugs <em>in vivo. In vitro</em> tests showed that ketoconazole (KTZ) was the most active drug, followed by TRB and CQL. The combinations itraconazole (ITZ)+CQL and ITZ+PH151 resulted in the highest percentages of synergism and none of the combinations resulted in antagonism. TRB showed the highest survival rates after seven days of treatment of the flies, followed by CQL and ITZ, whereas the evaluation of fungal burden of dead flies showed a greater fungicidal effect of azoles when compared to the other drugs. Here we showed for the first time that CQL is effective against <em>M. pachydermatis</em> and potentially interesting for the treatment of malasseziosis.</p></div>","PeriodicalId":14824,"journal":{"name":"Journal de mycologie medicale","volume":"34 2","pages":"Article 101475"},"PeriodicalIF":3.6,"publicationDate":"2024-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140103486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epidemiological, clinical, diagnostic, and therapeutic features of histoplasmosis: A systematic review","authors":"Adama Zida ,&nbsp;Thierry K Guiguemdé ,&nbsp;Marcel P Sawadogo ,&nbsp;Chanolle Tchekounou ,&nbsp;Ibrahim Sangaré ,&nbsp;Sanata Bamba","doi":"10.1016/j.mycmed.2024.101474","DOIUrl":"https://doi.org/10.1016/j.mycmed.2024.101474","url":null,"abstract":"<div><p>Histoplasmosis is a mycosis due to a dimorphic fungus <em>Histoplasma capsulatum</em>. This study aimed at providing an overview of histoplasmosis epidemiological, clinical, diagnostic, and therapeutic aspects from the last 30 years.</p><p>This review was carried out using a systematic literature search on histoplasmosis from 1992 to 2021. We describe the clinical features, diagnostic methods and treatment. Empirical searches were conducted via the databases PubMed, Google Scholar and Science Direct.</p><p>Between 1992 and 2021, 190 manuscripts were published and reported 212 cases of histoplasmosis. These publications included 115 and 97 cases of American and African histoplasmosis respectively. The number of publications increased over the last ten years with a maximum in 2020 (12.34 % of the cases reported). The disseminated forms of histoplasmosis were the most frequently reported cases as compared to the localized forms. This was the case with the American histoplasmosis (75.65 %) as well as with the African histoplasmosis (55.67 %). Itraconazole (31.17 %) and Amphotericin B (26.62 %) were the most used drugs in the management of these cases.</p><p>American histoplasmosis is distributed worldwide whereas African histoplasmosis is mainly present in intertropical Africa. There is a critical need for setting up a global surveillance system, towards a better understanding of the disease.</p></div>","PeriodicalId":14824,"journal":{"name":"Journal de mycologie medicale","volume":"34 2","pages":"Article 101474"},"PeriodicalIF":3.6,"publicationDate":"2024-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140113904","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Disseminated phaeohyphomycosis due to Cladophialophora bantiana in an immunocompetent child","authors":"Aakash Mahesan ,&nbsp;Abin Sheref Mohammed ,&nbsp;Gautam Kamila ,&nbsp;Prashant Jauhari ,&nbsp;Biswaroop Chakrabarty ,&nbsp;Sumanta Das ,&nbsp;Prasenjit Das ,&nbsp;Vaishali Suri ,&nbsp;Sudesh Gourav ,&nbsp;Immaculata Xess ,&nbsp;Atin Kumar ,&nbsp;Sheffali Gulati","doi":"10.1016/j.mycmed.2024.101467","DOIUrl":"https://doi.org/10.1016/j.mycmed.2024.101467","url":null,"abstract":"<div><p>A 3-year-old boy presented with acute headache, vomiting and right focal clonic seizures without history of fever, joint pain or altered sensorium. Neuroimaging showed multifocal contrast enhancing lesions with significant perilesional edema. CECT chest and abdomen showed multiple variable sized nodules in the lungs and hypodense lesion in liver with mesenteric lymphadenopathy. There was persistent eosinophilia with maximum upto 35 %. Liver biopsy and brain biopsy revealed <em>Cladophialophora bantiana</em>. He was treated with IV liposomal amphotericin and voriconazole for 6 weeks with repeat neuroimaging showing more than 50 % resolution of the intracranial lesions. He was transitioned to oral combination of flucytosine and voriconazole. At 14 months follow-up, he remained symptom free with complete radiological resolution of the lesions and no eosinophilia. High suspicion, an aggressive approach in obtaining microbiological diagnosis and timely combination antifungal therapy may give satisfactory outcome without surgery.</p></div>","PeriodicalId":14824,"journal":{"name":"Journal de mycologie medicale","volume":"34 2","pages":"Article 101467"},"PeriodicalIF":3.6,"publicationDate":"2024-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140014103","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Estimated burden of fungal infections in Panama","authors":"Cristel Rodríguez-Vargas ,&nbsp;Ana Alastruey-Izquierdo ,&nbsp;David W. Denning ,&nbsp;Ana Belén Araúz","doi":"10.1016/j.mycmed.2024.101466","DOIUrl":"https://doi.org/10.1016/j.mycmed.2024.101466","url":null,"abstract":"<div><p>Data published on Panamanian fungal disease are scarce, mostly case reports. To date, there is no paper that compiles the burden of fungal disease Here we estimate for the first time the incidence and prevalence of fungal diseases in Panama. Data on fungal disease were obtained from different search engines: PubMed, Google Scholar, Scielo and Lilacs. For population and at risk diseases, we used statistics from worldometer, UNAIDS, and WHO. Incidence, prevalence, and absolute numbers were calculated based on the population at risk. Panamanian population in 2022 was 4,429,739. We estimated that 85,530 (1.93 %) people suffer from fungal diseases. The most frequent fungal infection was recurrent <em>Candida</em> vaginitis (3320/100,000). There are 31,000 HIV-infected people in Panama and based on the number of cases not receiving anti-retroviral therapy (14,570), and previous reports of prevalence of opportunistic infections, we estimated annual incidences of 4.0/100,000 for cryptococcal meningitis, 29.6/100,000 for oral candidiasis, 23.2/100,000 for esophageal candidiasis, 29.3/100,000 for <em>Pneumocystis</em> pneumonia, 15.1/100,000, and for histoplasmosis. For chronic pulmonary aspergillosis (CPA) and fungal asthma we used data from Guatemala and Colombia to estimate COPD and asthma prevalence and WHO report for tuberculosis. We estimated annual incidences of 6.1/100,000 for invasive aspergillosis and prevalence of 31.7/100,000 for CPA, 60.5/100,000 for allergic bronchopulmonary aspergillosis, and 79.9/100,000 for severe asthma with fungal sensitisation. Other incidence estimates were 5.0/100,000 for candidaemia, 0.20/100,000 for mucormycosis, and 4.99/100,000 for fungal keratitis. Even though this report on burden of fungal disease is a forward step, more epidemiological studies to validate these estimates are needed.</p></div>","PeriodicalId":14824,"journal":{"name":"Journal de mycologie medicale","volume":"34 1","pages":"Article 101466"},"PeriodicalIF":3.6,"publicationDate":"2024-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1156523324000076/pdfft?md5=0a35aee58e89374e39772a23c65fdc21&pid=1-s2.0-S1156523324000076-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139914918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative assessment of Sensititre YeastOne and Micronaut-AM EUCAST for antifungal susceptibility testing in candidaemia isolates","authors":"Florian Bélik,&nbsp;Corentin Deckers,&nbsp;Mehdi Khourssaji,&nbsp;Te-Din Huang,&nbsp;Olivier Denis,&nbsp;Isabel Montesinos","doi":"10.1016/j.mycmed.2024.101465","DOIUrl":"10.1016/j.mycmed.2024.101465","url":null,"abstract":"<div><h3>Purpose</h3><p>Antifungal susceptibility testing (AFST) is essential to ensure appropriate antifungal therapy in candidaemia. This study compared two commercial colorimetric broth microdilution tests: Sensititre YeastOne (SYO; Thermo Scientific) and Micronaut-AM EUCAST AFST (M-AM; Bruker) for the AFST of <em>Candida</em> spp.</p></div><div><h3>Material and Methods</h3><p>A total of 74 yeast strains, including <em>C. albicans</em> (<em>n</em> = 40) and non-<em>albicans Candida</em> species (NACS) (<em>n</em> = 34), were obtained from blood cultures of patients admitted to a tertiary care hospital in Belgium from 2017 to 2022. AFST by SYO and by M-AM were performed according to the manufacturers’ protocols and interpreted using CLSI and EUCAST guidelines, respectively. Essential and categorical agreements (EA and CA), very major, major and minor discrepancies were calculated for amphotericin B, echinocandins and azoles considering SYO as the reference method.</p></div><div><h3>Results</h3><p>In total, 441 and 392 isolate-antifungal results were evaluable for EA and CA, respectively. SYO and M-AM, showed a high level of concordance for <em>C. albicans</em> strains, with an EA and CA ≥90 % for all tested antifungals. However, we noted significant discordances for NACS, the lowest EA were observed with micafungin (50 %) and voriconazole (58.8 %). These discrepancies were likely due to differences in the raw MIC values obtained by the two methods and the different interpretation breakpoints used by CLSI and EUCAST.</p></div><div><h3>Conclusion</h3><p>Our study showed excellent agreement between SYO and M-AM for AFST of <em>C. albicans</em>, while the equivalency was lower for NACS. AFST method should be carefully selected, considering the results might impact the choice of antifungals for non-<em>albicans</em> candidaemia.</p></div>","PeriodicalId":14824,"journal":{"name":"Journal de mycologie medicale","volume":"34 1","pages":"Article 101465"},"PeriodicalIF":3.6,"publicationDate":"2024-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139827026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"In vitro determination of the combination of ciclopirox and terbinafine in the treatment of dermatophytosis","authors":"Bárbara da Costa ,&nbsp;Bruna Pippi ,&nbsp;Magda Chaves ,&nbsp;Giovanna Agostineto ,&nbsp;Alexandre Meneghello Fuentefria","doi":"10.1016/j.mycmed.2024.101464","DOIUrl":"https://doi.org/10.1016/j.mycmed.2024.101464","url":null,"abstract":"<div><h3>Introduction</h3><p>The cases of dermatophytosis are increasing and they are associated with a higher number of therapeutic failures leading the doctor to prescribe combinations of antifungals as therapy. The objective was to evaluate the interaction of terbinafine and ciclopirox, the most commonly antifungals used in the clinic, in dermatophyte isolates.</p></div><div><h3>Methodology</h3><p>The minimum inhibitory concentrations (MIC) of ciclopirox and terbinafine were determined by the broth microdilution method according CLSI and the checkerboard assay was used to evaluate the interaction between the antifungal agents.</p></div><div><h3>Results</h3><p>For terbinafine the mic50 was 0.125 ug/mL and mic90 was 0.250 ug/mL. For ciclopirox the values were 2.0 ug/mL for mic50 and 4.0 ug/mL for mic90. No synergistic interaction was observed for the dermatophyte isolates tested.</p></div><div><h3>Conclusion</h3><p>These results suggest that the use of terbinafine in combination with ciclopirox, which is widely used in the clinic, may not be a good choice for the treatment of onychomycosis.</p></div>","PeriodicalId":14824,"journal":{"name":"Journal de mycologie medicale","volume":"34 1","pages":"Article 101464"},"PeriodicalIF":3.6,"publicationDate":"2024-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139743907","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hormographiella aspergillata pulmonary infections: Detection and identification of the fungus using pan-fungal PCR assays and DNA sequencing","authors":"Gilles Nevez ,&nbsp;Gaelle Guillerm ,&nbsp;Jean-Philippe Talarmin ,&nbsp;Dorothée Quinio ,&nbsp;Xavier Iriart ,&nbsp;Pierre-Luc Lissillour ,&nbsp;Schéhérazade Rezig ,&nbsp;Marie-Sarah Fangous ,&nbsp;Marion Ranty ,&nbsp;Laetitia Bodenes ,&nbsp;Cécile Aubron ,&nbsp;Marie-Anne Couturier ,&nbsp;Solène Le Gal","doi":"10.1016/j.mycmed.2024.101463","DOIUrl":"10.1016/j.mycmed.2024.101463","url":null,"abstract":"<div><p><em>Hormographiella aspergillata</em> is a basidiomycete exceptionally involved in invasive fungal infections (IFI). We report a case of <em>H. aspergillata</em> pulmonary infection in a 30-year-old female in a context of pancytopenia and relapsed of acute myeloid leukemia (AML). She presented with fever, thoracic pain, left pleural effusion and pneumonia, diagnosed on chest X-ray and CT-scan. Direct examination of a bronchoalveolar lavage (BAL) specimen performed on day (d) 10 was negative, while the culture was positive on d30. <em>H. aspergillata</em> was suspected, considering macroscopic and microscopic examination. Its identification was confirmed using Microflex® Bruker mass spectrometry and pan-fungal (PF)-PCR assay followed by DNA sequencing. After this initial diagnosis, the patient was monitored for 2.8 years. She was treated with liposomal amphotericin B and/or voriconazole until switching to isavuconazole on d298 due to side-effects. This antifungal treatment was maintained until d717 and then discontinued, the patient being considered as cured. Over this follow-up period, the patient was submitted to recurrent pulmonary sampling. Each time, cultures were negative, while PF – PCR assays and DNA sequencing confirmed the presence of <em>H. aspergillata</em>. The present case-report is the 32nd observation of <em>H. aspergillata</em> invasive infection showing that this IFI is still infrequent. Fifteen have occurred in patients with AML, which appears as the most frequent underlying disease favoring this IFI. Six recent case-reports in addition to ours highlight PF-PCR assays and DNA sequencing as relevant diagnostic tools that must be included in routine diagnosis and monitoring of IFI, specifically those due to rare basidiomycetes<em>.</em></p></div>","PeriodicalId":14824,"journal":{"name":"Journal de mycologie medicale","volume":"34 1","pages":"Article 101463"},"PeriodicalIF":3.6,"publicationDate":"2024-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139717462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Invasive fungal rhinosinusitis by Fusarium proliferatum/annulatum in a patient with acute myeloid leukemia: A case report and review of the literature","authors":"Zeynep Cansu Caliskan ,&nbsp;Gizem Karahan ,&nbsp;Neslihan Koray ,&nbsp;Yasin Gokcinar ,&nbsp;Dolunay Gülmez ,&nbsp;Sevtap Arikan-Akdagli ,&nbsp;Serhat Unal ,&nbsp;Omrum Uzun","doi":"10.1016/j.mycmed.2024.101461","DOIUrl":"10.1016/j.mycmed.2024.101461","url":null,"abstract":"<div><p><span>Antifungal prophylaxis with a mold-effective agent has led to a substantial decrease in invasive infections caused by </span><span><em>Aspergillus</em></span><span> spp. in the management of patients with acute myeloid leukemia<span> undergoing induction chemotherapy. However, difficult-to-treat infections caused by other molds, such as </span></span><span><span><em>Fusarium</em><em>, Lomentospora, and </em></span><em>Scedosporium</em></span><span> species may still complicate the neutropenic period. Here, we present a case of a 23-year-old woman with acute myeloid leukemia who developed a breakthrough invasive fungal rhinosinusitis caused by </span><em>Fusarium proliferatum/annulatum</em><span> on posaconazole<span> prophylaxis. The infection was diagnosed using clinical, microbiological, and radiological criteria and the isolate was identified using Matrix Assisted Lazer Desorption Ionization Time of Flight Mass Spectrometry (MALDI-TOF MS) and sequencing. We searched Pubmed with “</span></span><span><em>Fusarium proliferatum</em></span>”, “<em>Fusarium annulatum</em>”, “immunosuppression AND fusariosis“, “rhinosinusitis AND <em>Fusarium proliferatum</em><span>” and summarized the English literature for similar rhinosinusitis cases infected with the same pathogen.</span></p></div>","PeriodicalId":14824,"journal":{"name":"Journal de mycologie medicale","volume":"34 1","pages":"Article 101461"},"PeriodicalIF":3.6,"publicationDate":"2024-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139583916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}